Q3 2020

Source filing unavailable

Q3 2020 · —

Revenue

$3.46M

no prior Q3 2019 on file

Net Income

-$3.30M

no prior Q3 2019 on file

EPS Diluted

-$0.96

no prior Q3 2019 on file

Gross Profit$2,482,792—

Operating Income-$2,336,421—

Operating Cash Flowderived

Same quarter

no prior Q3 2019 on file

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Petros Pharmaceuticals, Inc. · CIK 1815903 · Engraved from SEC EDGAR